Renata Grzywa

Dr. Renata Grzywa

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
AŁAgnieszka Łupicka-Słowik
Agnieszka Łupicka-Słowik
RGRenata Grzywa
Renata Grzywa
ELEwa Leporowska
Ewa Leporowska
DPDanuta Procyk
Danuta Procyk
JOJózef Oleksyszyn
Józef Oleksyszyn
MSMarcin Sieńczyk
Marcin Sieńczyk
Łupicka-Słowik A, et al. Ann Lab Med. 2019 Jul;39(4):373-380. https://doi.org/10.3343/alm.2019.39.4.373

22 December 2014 in Bioanalysis
Verified
Journal Article
Closed access
AŁAgnieszka Łupicka-Słowik
Agnieszka Łupicka-Słowik
MWMaciej Walczak
Maciej Walczak
RGRenata Grzywa
Renata Grzywa
BKBobrek Kamila
Bobrek Kamila
MŁMaria Łęcka
Maria Łęcka
MSMarcin Sieńczyk
Marcin Sieńczyk
The prostate-specific antigen (PSA) is considered an important serum marker for prostate cancer detection, monitoring and staging. The purpose of this study was to generate IgY class antibodies that recognize native PSA and selected epitopes. Hens immunized with either full-length human PSA or its peptidyl fragment-conjugates produced specific antibodies that were isolated from egg yolks. We developed a monoclonal/IgY sandwich ELISA with a PSA detection limit of 50 pg/ml and a linear range of 0.05-1.0 ng/ml. Because the signal observed for the PSA-specific IgY antibodies by ELISA and the reactivity profile of the epitope-derived IgYs were comparable to those of mouse monoclonal IgG antibodies, avian antibodies may be a cost-effective alternative to mammalian antibodies for prostate cancer diagnostics.

1 November 2019 in Biochimie
Verified
Journal Article
Closed access
RGRenata Grzywa
Renata Grzywa
ALAdam Lesner
Adam Lesner
BKBRICE KORKMAZ
BRICE KORKMAZ
MSMarcin Sieńczyk
Marcin Sieńczyk

Verified
Journal Article
Open access
PDF file
RGRenata Grzywa
Renata Grzywa
MPMateusz Psurski
Mateusz Psurski
AGAnna Gajda
Anna Gajda
TGTadeusz Gajda
Tadeusz Gajda
ŁJŁukasz Janczewski
Łukasz Janczewski
Among the various substances that interfere with the microtubule formation process, isothiocyanates (ITCs) are the group of compounds for which the binding mode and mechanism of action have not yet been explained. To better understand the structure–activity relationship of tubulin-isothiocyanate interactions, we designed and synthesized a series of sixteen known and novel, structurally diverse ITCs, including amino acid ester-derived isothiocyanates, bis-isothiocyanates, analogs of benzyl isothiocyanate, and phosphorus analogs of sulforaphane. All synthesized compounds and selected natural isothiocyanates (BITC, PEITC, AITC, and SFN) were tested in vitro to evaluate their antiproliferative activity, tubulin polymerization inhibition potential, and influence on cell cycle progression. The antiproliferative activity of most of the newly tested compounds exceeded the action of natural isothiocyanates, with four structures being more potent as tubulin polymerization inhibitors than BITC. As a confirmation of anti-tubulin activity, the correlation between polymerization inhibition and cell cycle arrest in the G2/M phase was observed for the most active compounds. In light of the biological results indicating significant differences in the impact of structurally diverse isothiocyanate on tubulin polymerization, in silico analysis was conducted to analyze the possible mode of isothiocyanate-tubulin binding and to show how it can influence the polymerization reaction.

20 April 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AAAkmaral Assylbekova
Akmaral Assylbekova
AZAnuar Zhanapiya
Anuar Zhanapiya
RGRenata Grzywa
Renata Grzywa
MSMarcin Sieńczyk
Marcin Sieńczyk
CSChristian Schönbach
Christian Schönbach
TBTimo Burster
Timo Burster
Coronavirus disease 2019 (COVID-19) can lead to multi-organ failure influenced by comorbidities and age. Binding of the severe acute respiratory syndrome coronavirus 2 spike protein (SARS-CoV-2 S protein) to angiotensin-converting enzyme 2 (ACE2), along with proteolytic digestion of the S protein by furin and transmembrane protease serine subtype 2 (TMPRSS2), provokes internalization of SARS-CoV-2 into the host cell. Productive infection occurs through viral replication in the cytosol and cell-to-cell transmission. The catalytic activity of TMPRSS2 can be blocked by the trypsin-like serine protease inhibitor camostat, which impairs infection by SARS-CoV-2. At the site of infection, immune cells, such as neutrophils, infiltrate and become activated, releasing neutrophil serine proteases (NSPs), including cathepsin G (CatG), neutrophil elastase (NE), and proteinase 3 (PR3), which promote the mounting of a robust immune response. However, NSPs might be involved in infection and the severe outcome of COVID-19 since the uncontrolled proteolytic activity is responsible for many complications, including autoimmunity, chronic inflammatory disorders, cardiovascular diseases, and thrombosis. Here, we demonstrate that camostat does not inhibit the catalytic activity of CatG, NE, and PR3, indicating the need for additional selective serine protease inhibitors to reduce the risk of developing severe COVID-19.

29 January 2020 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
KNKoffi N’guessan
Koffi N’guessan
RGRenata Grzywa
Renata Grzywa
SSSeda Seren
Seda Seren
GGGuillaume Gabant
Guillaume Gabant
MJMaria A. Juliano
Maria A. Juliano
BKBRICE KORKMAZ
BRICE KORKMAZ
Polymorphonuclear neutrophils contain at least four serine endopeptidases, namely neutrophil elastase (NE), proteinase 3 (PR3), cathepsin G (CatG), and NSP4, which contribute to the regulation of infection and of inflammatory processes. In physiological conditions, endogenous inhibitors including α2‐macroglobulin (α2‐M), serpins [α1‐proteinase inhibitor (α1‐PI)], monocyte neutrophil elastase inhibitor (MNEI), α1‐antichymotrypsin, and locally produced chelonianins (elafin, SLPI) control excessive proteolytic activity of neutrophilic serine proteinases. In contrast to human NE (hNE), hPR3 is weakly inhibited by α1‐PI and MNEI but not by SLPI. α2‐M is a large spectrum inhibitor that traps a variety of proteinases in response to cleavage(s) in its bait region. We report here that α2‐M was more rapidly processed by hNE than hPR3 or hCatG. This was confirmed by the observation that the association between α2‐M and hPR3 is governed by a kass in the ≤ 105 m−1·s−1 range. Since α2‐M‐trapped proteinases retain peptidase activity, we first predicted the putative cleavage sites within the α2‐M bait region (residues 690–728) using kinetic and molecular modeling approaches. We then identified by mass spectrum analysis the cleavage sites of hPR3 in a synthetic peptide spanning the 39‐residue bait region of α2‐M (39pep‐α2‐M). Since the 39pep‐α2‐M peptide and the corresponding bait area in the whole protein do not contain sequences with a high probability of specific cleavage by hPR3 and were indeed only slowly cleaved by hPR3, it can be concluded that α2‐M is a poor inhibitor of hPR3. The resistance of hPR3 to inhibition by endogenous inhibitors explains at least in part its role in tissue injury during chronic inflammatory diseases and its well‐recognized function of major target autoantigen in granulomatosis with polyangiitis.